RESPECT ESUS: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of undetermined Source
Jan 22, 2016
There is uncertainty over the optimal stroke prevention treatment for patients with ESUS. The current treatment recommendations of ASA alone, sometimes given with clopidogrel or ticlopidine (P08-06684, P08-08481) are based on limited data.
There is s...
Clinical Studies -
Jan 22, 2016 - Jan 1, 2018
Automatically Closed
Project leader: Kägi Georg
Members: Vehoff Jochen, Mbialeu Suzie
more
